Alan L Crane insider trades: Pandion Therapeutics (PAND) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Alan reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 21, 2020 | PAND | ↑ Buy | 36,111 | $18.00 | $650K | Indirect | Jul 21, 2020 (0d) |
| Jul 21, 2020 | PAND | ↑ Buy | 14,000 | $18.00 | $252K | Direct | Jul 21, 2020 (0d) |
| Aug 12, 2014 | TTOO | ↑ Buy | 30,000 | $11.00 | $330K | Direct | Aug 14, 2014 (2d) |
| Apr 15, 2014 | CERU | ↑ Buy | 1,470,582 | $7.00 | $10.3M | Indirect | Apr 15, 2014 (0d) |
| Jan 10, 2007 | MNTA | ↓ Sell | 49,700 | $17.46 | $868K | Direct | Jan 12, 2007 (2d) |
| Jan 10, 2007 | MNTA | ↓ Sell | 300 | $17.60 | $5K | Direct | Jan 12, 2007 (2d) |
| Dec 18, 2006 | MNTA | ↓ Sell | 62,500 | $16.46 | $1.0M | Direct | Dec 20, 2006 (2d) |
| Dec 8, 2006 | MNTA | ↓ Sell | 50,000 | $17.59 | $880K | Direct | Dec 12, 2006 (4d) |
| Nov 16, 2006 | MNTA | ↓ Sell | 61,200 | $16.33 | $1000K | Direct | Nov 20, 2006 (4d) |
| Nov 16, 2006 | MNTA | ↓ Sell | 1,300 | $16.36 | $21K | Direct | Nov 20, 2006 (4d) |
| Nov 8, 2006 | MNTA | ↓ Sell | 50,000 | $15.22 | $761K | Direct | Nov 13, 2006 (5d) |
| Oct 13, 2006 | MNTA | ↓ Sell | 30,232 | $15.00 | $453K | Direct | Oct 16, 2006 (3d) |
| Oct 11, 2006 | MNTA | ↓ Sell | 20,056 | $15.00 | $301K | Direct | Oct 12, 2006 (1d) |
| Sep 12, 2006 | MNTA | ↓ Sell10b5-1 | 88,174 | $15.01 | $1.3M | Direct | Sep 13, 2006 (1d) |
| Sep 7, 2006 | MNTA | ↓ Sell | 12,402 | $15.35 | $190K | Direct | Sep 11, 2006 (4d) |
| Sep 5, 2006 | MNTA | ↓ Sell | 21,600 | $15.90 | $343K | Direct | Sep 7, 2006 (2d) |
| Aug 31, 2006 | MNTA | ↓ Sell | 83,000 | $16.41 | $1.4M | Direct | Sep 1, 2006 (1d) |
| Aug 9, 2006 | MNTA | ↓ Sell | 29,700 | $15.24 | $453K | Direct | Aug 10, 2006 (1d) |
| Aug 8, 2006 | MNTA | ↓ Sell | 20,300 | $15.61 | $317K | Direct | Aug 10, 2006 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Alan L Crane's insider trades
Alan L Crane is a director at Pandion Therapeutics (PAND). Since Aug 8, 2006, Alan has reported 4 open-market purchases worth $11.5M and 15 sales worth $9.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (14% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (9 filings), option exercises (5 filings), shares returned to the company (4 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PAND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.